One of the possible mechanisms for the higher incidence of pneumonia with PD-1 inhibitors lies in blocking the interaction between PD-L2 (programmed cell death-ligand 2 inhibitors) and PD-1 through PD-1. This evidence concerns the gene PDCD1 and pneumonia.